TY - JOUR
T1 - Consensus review and considerations on TMS to treat depression
T2 - A comprehensive update endorsed by the National Network of Depression Centers, the Clinical TMS Society, and the International Federation of Clinical Neurophysiology
AU - National Network of Depression Centers Neuromodulation Task Group
AU - Trapp, Nicholas T.
AU - Purgianto, Anthony
AU - Taylor, Joseph J.
AU - Singh, Manpreet K.
AU - Oberman, Lindsay M.
AU - Mickey, Brian J.
AU - Youssef, Nagy A.
AU - Solzbacher, Daniela
AU - Zebley, Benjamin
AU - Cabrera, Laura Y.
AU - Conroy, Susan
AU - Cristancho, Mario
AU - Richards, Jackson R.
AU - Flood, Michael J.
AU - Barbour, Tracy
AU - Blumberger, Daniel M.
AU - Taylor, Stephan F.
AU - Feifel, David
AU - Reti, Irving M.
AU - McClintock, Shawn M.
AU - Lisanby, Sarah H.
AU - Husain, Mustafa M.
N1 - Publisher Copyright:
© 2024 International Federation of Clinical Neurophysiology
PY - 2025/2
Y1 - 2025/2
N2 - This article updates the prior 2018 consensus statement by the National Network of Depression Centers (NNDC) on the use of transcranial magnetic stimulation (TMS) in the treatment of depression, incorporating recent research and clinical developments. Publications on TMS and depression between September 2016 and April 2024 were identified using methods informed by PRISMA guidelines. The NNDC Neuromodulation Work Group met monthly between October 2022 and April 2024 to define important clinical topics and review pertinent literature. A modified Delphi method was used to achieve consensus. 2,396 abstracts and manuscripts met inclusion criteria for review. The work group generated consensus statements which include an updated narrative review of TMS safety, efficacy, and clinical features of use for depression. Considerations related to training, roles/responsibilities of providers, and documentation are also discussed. TMS continues to demonstrate broad evidence for safety and efficacy in treating depression. Newer forms of TMS are faster and potentially more effective than conventional repetitive TMS. Further exploration of targeting methods, use in special populations, and accelerated protocols is encouraged. This article provides an updated overview of topics relevant to the administration of TMS for depression and summarizes expert, consensus opinion on the practice of TMS in the United States.
AB - This article updates the prior 2018 consensus statement by the National Network of Depression Centers (NNDC) on the use of transcranial magnetic stimulation (TMS) in the treatment of depression, incorporating recent research and clinical developments. Publications on TMS and depression between September 2016 and April 2024 were identified using methods informed by PRISMA guidelines. The NNDC Neuromodulation Work Group met monthly between October 2022 and April 2024 to define important clinical topics and review pertinent literature. A modified Delphi method was used to achieve consensus. 2,396 abstracts and manuscripts met inclusion criteria for review. The work group generated consensus statements which include an updated narrative review of TMS safety, efficacy, and clinical features of use for depression. Considerations related to training, roles/responsibilities of providers, and documentation are also discussed. TMS continues to demonstrate broad evidence for safety and efficacy in treating depression. Newer forms of TMS are faster and potentially more effective than conventional repetitive TMS. Further exploration of targeting methods, use in special populations, and accelerated protocols is encouraged. This article provides an updated overview of topics relevant to the administration of TMS for depression and summarizes expert, consensus opinion on the practice of TMS in the United States.
UR - http://www.scopus.com/inward/record.url?scp=85213951635&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85213951635&partnerID=8YFLogxK
U2 - 10.1016/j.clinph.2024.12.015
DO - 10.1016/j.clinph.2024.12.015
M3 - Review article
C2 - 39756350
AN - SCOPUS:85213951635
SN - 1388-2457
VL - 170
SP - 206
EP - 233
JO - Clinical Neurophysiology
JF - Clinical Neurophysiology
ER -